Rizatriptan in migraine

Expert Review of Neurotherapeutics

Volumn 5, Issue 5, 2005, Pages 597-603

  Krymchantowski, Abouch Valenty ^a   Bigal, Marcelo Eduardo ^b  

^a Instituto de Neurologia Deolindo Couto   (Brazil)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acute treatment; Migraine; Rizatriptan

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ELETRIPTAN; ERGOTAMINE; FROVATRIPTAN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ASTHENIA; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; META ANALYSIS; MIGRAINE; NAUSEA; NECK PAIN; PAIN; PAIN ASSESSMENT; PARAMETER; PARESTHESIA; PHARMACODYNAMICS; PHOTOPHOBIA; PREVALENCE; REVIEW; SENSORY DYSFUNCTION; SOMNOLENCE; THORAX PAIN; TREATMENT OUTCOME; XEROSTOMIA;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; DRUG TOXICITY; EXPERT TESTIMONY; HUMANS; META-ANALYSIS; MIGRAINE DISORDERS; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 26444433251     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.5.5.597     Document Type: Review

References (42)

1. Stewart WF, Lipton RB, Simon D. Work-related disability, results from the American migraine study. Cephalalgia 16, 231-238 (1996).
2. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity, and attack frequency and duration. Neurology 44(Suppl. 14), S24-S39 (1994).
3. Rasmussen BK. Epidemiology of Headache. Cephalalgia 15, 45-68 (1995).
4. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol. Clin. 15, 1-13 (1997).
5. Saxena P, Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA. 411-438 (2000).
6. Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 38, 18-22 (1998).
7. Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 44(7), 661-668 (2004).
8. Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan - nonresponders: a survey in 366 migraine patients. Headache 36, 471-475 (1996).
9. Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia 15(Suppl. 15), 21-28 (1995).
10. Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47, 46-51 (1996).
11. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurology 4(1), 10 (2004).
12. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol. 55(1), 19-26 (2004). Highlights the importance of using triptans and other acute teratments early in a migraine attack to avoid the development of cutaneous allodynia.
13. Maxalt® (rizatriptan) tablets. In: Physicians Desk Reference®. 53rd Edition, Medical Economics Company, NJ, USA. 1822-1827 (1999).
14. Hargreaves RJ, Longmore J, Beer M et al. The pharmacology and mechanisms of action of rizatriptan. In: Drug Treatment of Migraine and Other Headaches Diener HC (Ed.). Karger, Basel, Switzerland. Monogr. Clin. Neurosci. 17, 141-161 (2000).
15. 1A receptor agonist. In: Cardiovascular Pharmacology of 5-Hydroxytriptamine. Saxena PR, Wallis DA, Wouters W, Bevan P (Eds). Kluwer Academic Publishers, London, UK. 355-359 (1990).
16. Siedelin KN, Tfelt-Hansen P, Mendel CN, Stepanavage M. Peripheral hemodynamic study of MK-462, ergotamine, and their combination in humans. Cephalalgia 15(Suppl. 14), 207 (2000).
17. 1D agonist. Br. J. Clin. Phamacol. 4349-4354 (1995).
18. Lee Y, Conroy JA, Stepanavage ME et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br. J. Clin. Pharmacol. 47, 373-378 (1999).
19. Cutler NR, Jhee SS, Majumdar AK et al. Pharmacokinetics of rizatriptan tablets during and between migraine attacks. Headache 39, 264-269 (1999).
20. 1B/1D agonist for migraine. Headache 37, 310 (1997).
21. IHS Committee on Clinical Trials in Migraine. Guidelines for controlled trials in migraine. Cephalalgia 11, 1-12 (1991).
22. Gjsman H, Kramer MS, Sargent J et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 17, 647-651 (1997).
23. Teall J, Tuchman M, Cutler N et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, out-patient study. Headache 38, 281-287 (1998).
24. Tfelt-Hansen P, Teall J, Rodriguez F et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 38, 748-755 (1998).
25. Kramer MS, Matzura-Wolfe D, Polis A et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology 51, 773-781 (1998).
26. Dahlof C, Lines C. Rizatriptan - therapy. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Karger, Basel, Switzerland. 17, 162-172 (2000).
27. Ahrens SP, Farmer MV, Williams DL et al. and the Rizatriptan Wafer Protocol 049 Study Group. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 19, 525-530 (1999).
28. Klapper JA, O'Connor S. Rizatriptan wafer-sublingual vs. placebo at the onset of acute migraine. Cephalalgia 20, 585-587 (2000).
29. 1B/1D agonists) in acute treatment: a meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001).
30. Dahlof C, Lipton RB, McCarroll KA et al. Within-patient consistency of response of rizatriptan fro treating migraine. Neurology 55, 1511-1516 (2000).
31. Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur. Neurol. 49, 20-29 (2003).
32. Lines C, Visser WH, Vandormael K, Reines SA. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache 37, 319-320 (1997).
33. Block GA, Goldstein J, Polis A, Reines SA, Smith ME. Efficacy and safety of rizatriptan versus standard care during long-term treatment of migraine. Headache 38, 764-771 (1998).
34. Dodick D, Lipton RB, Martin V et al. Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 44(5), 414-425 (2004). Clarifies cardiovascular safety issues ceoncerning the use of triptans in migraine.
35. Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 62, 563-568 (2004).
36. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 39, S20-S26 (1999).
37. Diener HC. Eletriptan in migraine. Expert Rev. Neurotherapeutics 5(1), 43-53 (2005).
38. Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: a retrospective analysis of data from three clinical trials. Clin. Ther. 22, 1035-1048 (2000).
39. Krymchantowski AV. Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurologia 28(4), 1-4 (2004). Raise the issue of combining acute migraine treatments using triptans and its advantages in terms of efficacy, tolerability and outcome.
40. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib versus rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22, 309-312 (2002).
41. Krymchantowski AV, Bigal ME, Moreira PF. Rizatriptan versus rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Neurology 64(Suppl. 1), A348 (2005) (Abstract).
42. Krymchantowski AV. Combining therapies for the treatment of migraine: is there a role? Expert Rev. Neurotherapeutics 5(2), 145-147 (2005).